2006, Number S2
<< Back Next >>
Arch Cardiol Mex 2006; 76 (S2)
ST elevation acute coronary syndromes. Pharmaco-mechanic strategy is the universal treatment future?
Juárez HU
Language: Spanish
References: 12
Page: 252-257
PDF size: 92.65 Kb.
ABSTRACT
The main objective in the medical treatment of
the ST elevation acute myocardial infarction,
must have the intention to reperfuse the culprit
involved artery. In order to reduce this time, the
pharmaco-invasive strategy may offer rapid flow
recanalization in the culprit artery and reduce
the damage of the myocardium. The new pharmacologic
combinations includes half dose of
fibrinolytics, alone or in combination with IIb/IIIa
inhibitors, this combination may offer advantages
of the flow. This concept involves the that PCI
(Percutaneous Coronary Interventions), can be
done in a subsequent time. The risk of bleeding
is increased with this strategy, and some evaluation
or bleeding risk must be done in all patients,
as in patients with 75 years and older.
REFERENCES
REMIER KA, LOWE JE, RASMUSSEN M, JENINNGS R: The wave front phenomenon of ischemic cell death. 1 Myocardial size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.
OHMAN EM, CALIFF RM, TOPOL EJ, CANDELA R, ABBOTTSMITH C, ELLIS S, SIGMON KN, KEREIAKES D, GEORGE B, STACK R: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group: Circulation 1990; 82: 781-791.
GIBBSON M, CANNON C, PIANA R, ET AL: Angiographic predictors of reocclusion after thrombolysis: Results from the thrombolysis in myocardial infarction (TIMI) 4 Trial. JACC 1995; 25: 582-589.
STEG G, BONNEFOY E, CHABAUD S, ET AL: Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
DE LUCA G, SURYAPRANATA H, ZIJLSTRA F: Symptom onset to balloon time and mortality in patients with acute myocardial infarction treated with primary angioplasty. JACC 2003; 42: 991-997.
BONNEFOY E, LAPOSTOLLE F, LEIZOROVICZ A, ET AL: Primary PTCA vs Pre-hospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360: 825-829.
DANCHIN N, BLANCHARD D, STEG PG, SAUVAL P, HANANIA G, GOLDSTEIN P, CAMBOU JP, GUERET P, VAUR L, BOUTALBI Y, GENES N, LABLANCHE JM, USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry: Circulation 2004; 110: 1909-1915.
WIDIMSKY P, GROCH L, ZELÍZKO M, ET AL: Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The Prague study. Eur Heart Journal 2000; 21: 823-31.
DAUERMAN H, SOBEL B, ET AL: Synergistic treatment of ST elevation myocardial infarction with pharmacoinvasive recanalization. JACC ; 42: 646-51.
MARTÍNEZ M, ROSAS M, GONZÁLEZ H, ET AL: Comparison of reperfusion regimens with or without tirofiban in ST elevation acute myocardial infarction. SASTRE. Am J Cardiol 2004; 93: 280-287.
ASSENT-4-PCI: Full dose of TNK plus primary PTCA vs primary PTCA in acute myocardial infarction. (presentación oral en el Congreso Europeo de Cardiología. Estocolmo Suecia Agosto del 2005).
ANTMAN E, VAN DER WERF: Pharmaco-invasive therapy. The future of treatment for ST elevation myocardial infarction. Circulation 2004; 109: 2480-86.
Full text